[go: up one dir, main page]

MX2014001377A - Metodo para detectar cancer pancreatico. - Google Patents

Metodo para detectar cancer pancreatico.

Info

Publication number
MX2014001377A
MX2014001377A MX2014001377A MX2014001377A MX2014001377A MX 2014001377 A MX2014001377 A MX 2014001377A MX 2014001377 A MX2014001377 A MX 2014001377A MX 2014001377 A MX2014001377 A MX 2014001377A MX 2014001377 A MX2014001377 A MX 2014001377A
Authority
MX
Mexico
Prior art keywords
pancreatic cancer
detecting pancreatic
antibody
caprin
protein
Prior art date
Application number
MX2014001377A
Other languages
English (en)
Other versions
MX349907B (es
Inventor
Fumiyoshi Okano
Takayoshi Ido
Original Assignee
Toray Industries
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toray Industries filed Critical Toray Industries
Publication of MX2014001377A publication Critical patent/MX2014001377A/es
Publication of MX349907B publication Critical patent/MX349907B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4738—Cell cycle regulated proteins, e.g. cyclin, CDC, INK-CCR
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/303—Liver or Pancreas
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G01N33/57525—
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente invención se refiere a un método para detectar cáncer pancreático que utiliza un nuevo marcador tumoral. Más específicamente, la presente invención proporciona lo siguiente: un método para detectar cáncer pancreático que incluye ensayar la existencia o cantidad de un polipéptido reactivo que se une a un anticuerpo contra la proteína CAPRIN-1 a través de una reacción antígeno-anticuerpo en una muestra aislada a partir de un sujeto de prueba; un reactivo para la detección de cáncer pancreático que incluye un anticuerpo contra la proteína CAPRIN-1 o un fragmento de la misma, y un polinucleótido que codifica para un anticuerpo de este tipo, y un kit.
MX2014001377A 2011-08-04 2012-08-03 Metodo para detectar cancer pancreatico. MX349907B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2011171364 2011-08-04
PCT/JP2012/069824 WO2013018885A1 (ja) 2011-08-04 2012-08-03 膵臓癌の検出方法

Publications (2)

Publication Number Publication Date
MX2014001377A true MX2014001377A (es) 2014-03-21
MX349907B MX349907B (es) 2017-08-18

Family

ID=47629399

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014001377A MX349907B (es) 2011-08-04 2012-08-03 Metodo para detectar cancer pancreatico.

Country Status (16)

Country Link
US (1) US9796775B2 (es)
EP (1) EP2741085B1 (es)
JP (1) JP6094220B2 (es)
KR (1) KR101984554B1 (es)
CN (1) CN103718045B (es)
AU (1) AU2012290948B2 (es)
BR (1) BR112014002616B1 (es)
CA (1) CA2844033C (es)
DK (1) DK2741085T3 (es)
ES (1) ES2629061T3 (es)
HU (1) HUE033628T2 (es)
MX (1) MX349907B (es)
PL (1) PL2741085T3 (es)
PT (1) PT2741085T (es)
RU (1) RU2624040C2 (es)
WO (1) WO2013018885A1 (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2732980C (en) 2008-08-05 2017-08-15 Toray Industries, Inc. Caprin-1 as a target for diagnosing cancer
PL2322221T3 (pl) * 2008-08-05 2015-01-30 Toray Industries Kompozycja farmaceutyczna do leczenia i zapobiegania raka
ES2691738T3 (es) 2010-02-04 2018-11-28 Toray Industries, Inc. Agente farmacéutico para el tratamiento y/o la prevención de cáncer
CN102822335B (zh) 2010-02-04 2015-09-30 东丽株式会社 癌的治疗和/或预防用药物组合物
PT2532366T (pt) 2010-02-04 2016-12-20 Toray Industries Composição farmacêutica para o tratamento e/ou prevenção de cancro
MX340016B (es) 2010-02-04 2016-06-22 Toray Industries Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
DK2532680T3 (da) 2010-02-04 2015-07-20 Toray Industries Medicinsk sammensætning til behandling og/eller forebyggelse af cancer
EP2532365B1 (en) 2010-02-04 2016-05-04 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of cancer
HUE033628T2 (en) 2011-08-04 2017-12-28 Toray Industries Method for detecting pancreatic cancer
US9273128B2 (en) 2011-08-04 2016-03-01 Toray Industries, Inc Pharmaceutical composition for treatment and/or prophylaxis of cancer
CN103764825B (zh) 2011-08-04 2015-09-02 东丽株式会社 癌的治疗和/或预防用药物组合物
PL2740794T3 (pl) 2011-08-04 2018-09-28 Toray Industries, Inc. Kompozycja farmaceutyczna do leczenia i/lub profilaktyki nowotworów
CN103717238B (zh) 2011-08-04 2016-10-12 东丽株式会社 胰癌的治疗和/或预防用药物组合物
CA2844038C (en) 2011-08-04 2019-05-07 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prophylaxis of cancer
US9180188B2 (en) 2011-08-04 2015-11-10 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prophylaxis of cancer
MX363136B (es) * 2012-02-21 2019-03-12 Toray Industries Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
DK2818482T3 (da) 2012-02-21 2019-07-15 Toray Industries Farmaceutisk sammensætning til behandling af cancer
ES2739380T3 (es) 2012-02-21 2020-01-30 Toray Industries Composición farmacéutica para el tratamiento del cáncer
ES2643241T3 (es) 2012-02-21 2017-11-21 Toray Industries, Inc. Composición medicinal para tratar y/o prevenir el cáncer
JP6107655B2 (ja) * 2012-03-30 2017-04-05 東レ株式会社 胆嚢癌の治療及び／又は予防用医薬組成物
RU2640245C2 (ru) * 2012-03-30 2017-12-27 Торэй Индастриз, Инк. Фармацевтическая композиция для лечения и/или предотвращения рака печени
CN104471404B (zh) 2012-07-19 2017-03-01 东丽株式会社 癌的检测方法
HUE043162T2 (hu) 2012-07-19 2019-08-28 Toray Industries Eljárás rák detektálására
CA2918989C (en) 2013-08-09 2021-11-02 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of cancer
RU2612082C1 (ru) * 2015-10-14 2017-03-02 Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения Российской Федерации Способ прогнозирования направленности патологического процесса при раке головки поджелудочной железы
CA3029902A1 (en) 2016-07-07 2018-01-11 The Board Of Trustees Of The Leland Stanford Junior University Antibody adjuvant conjugates
CA3130794A1 (en) 2019-03-15 2020-09-24 Bolt Biotherapeutics, Inc. Immunoconjugates targeting her2
RU2712921C1 (ru) * 2019-08-12 2020-02-03 Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения Российской Федерации Способ индивидуального прогнозирования сроков прогрессирования плоскоклеточного рака пищевода II-III стадии после хирургического лечения
JPWO2022138460A1 (es) * 2020-12-24 2022-06-30
CN119306830B (zh) * 2023-07-11 2025-06-20 东莞市朋志生物科技有限公司 抗皮质醇抗体、检测皮质醇的试剂和试剂盒

Family Cites Families (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU714966B2 (en) 1994-09-19 2000-01-13 Ricardo J Moro Detection and treatment of cancer
US5698396A (en) 1995-06-07 1997-12-16 Ludwig Institute For Cancer Research Method for identifying auto-immunoreactive substances from a subject
US20030118599A1 (en) 1999-04-02 2003-06-26 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
RU2234942C2 (ru) 1998-07-14 2004-08-27 Корикса Корпорейшн Выделенный опухолевый полипептид предстательной железы и кодирующий его полинуклеотид
CZ2001149A3 (cs) 1998-07-14 2002-02-13 Corixa Corporation Prostředky a způsoby pro terapii a diagnostiku karcinomu prostaty
GB9815909D0 (en) 1998-07-21 1998-09-16 Btg Int Ltd Antibody preparation
US6969518B2 (en) 1998-12-28 2005-11-29 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
US6335170B1 (en) 1999-02-22 2002-01-01 Torben F. Orntoft Gene expression in bladder tumors
JP2002540790A (ja) 1999-04-02 2002-12-03 コリクサ コーポレイション 肺癌の治療および診断のための化合物ならびにその使用のための方法
US6444425B1 (en) 1999-04-02 2002-09-03 Corixa Corporation Compounds for therapy and diagnosis of lung cancer and methods for their use
US6949245B1 (en) 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
JP2003528587A (ja) 1999-10-29 2003-09-30 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド ２７個のヒト分泌タンパク質
US20020006404A1 (en) 1999-11-08 2002-01-17 Idec Pharmaceuticals Corporation Treatment of cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications
CA2404233A1 (en) 2000-03-29 2001-10-04 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US7919467B2 (en) 2000-12-04 2011-04-05 Immunotope, Inc. Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
US7408041B2 (en) 2000-12-08 2008-08-05 Alexion Pharmaceuticals, Inc. Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
US20040029114A1 (en) 2001-01-24 2004-02-12 Eos Technology, Inc. Methods of diagnosis of breast cancer, compositions and methods of screening for modulators of breast cancer
RU2306952C2 (ru) 2001-01-31 2007-09-27 Байоджен Айдек Инк. Лечение в-клеточных злокачественных опухолей с использованием комбинации применений, связанных с антителами, уменьшающими количество b-клеток, и с иммуномодулирующими антителами
AU2002311787A1 (en) 2001-03-28 2002-10-15 Zycos Inc. Translational profiling
WO2002083070A2 (en) 2001-04-10 2002-10-24 Corixa Corporation Compounds for immunotherapy and diagnosis of colon cancer and methods for their use
EP1516049A4 (en) 2001-05-11 2006-01-11 Corixa Corp COMPOSITIONS AND METHODS FOR THE THERAPY AND DIAGNOSIS OF LUNG CANCER
US20030190640A1 (en) 2001-05-31 2003-10-09 Mary Faris Genes expressed in prostate cancer
US7101977B2 (en) 2001-07-17 2006-09-05 Research Development Foundation Therapeutic agents comprising pro-apoptotic proteins
RU2319709C2 (ru) 2001-07-17 2008-03-20 Рисерч Дивелопмент Фаундейшн Терапевтические агенты, содержащие проапоптозные белки
US20040142325A1 (en) 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
EP2388265A1 (en) 2002-02-22 2011-11-23 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
US20050003390A1 (en) 2002-05-17 2005-01-06 Axenovich Sergey A. Targets for controlling cellular growth and for diagnostic methods
US20040126379A1 (en) 2002-08-21 2004-07-01 Boehringer Ingelheim International Gmbh Compositions and methods for treating cancer using cytotoxic CD44 antibody immunoconjugates and chemotherapeutic agents
WO2004047728A2 (en) 2002-11-26 2004-06-10 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
WO2004076682A2 (en) 2003-02-26 2004-09-10 Surromed, Inc. Targets for controlling cellular growth and for diagnostic methods
WO2004097051A2 (en) 2003-04-29 2004-11-11 Wyeth Methods for diagnosing aml and mds differential gene expression
US20050009067A1 (en) * 2003-05-19 2005-01-13 Craig Logsdon Expression profile of pancreatic cancer
US20060019256A1 (en) 2003-06-09 2006-01-26 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
WO2005007830A2 (en) 2003-07-14 2005-01-27 Mayo Foundation For Medical Education And Research Methods and compositions for diagnosis, staging and prognosis of prostate cancer
US20050032113A1 (en) 2003-07-17 2005-02-10 Mitsubishi Pharma Corporation Membrane protein library for proteome analysis and method for preparing same
CA2553826A1 (en) 2004-01-26 2005-12-08 Debiovision Inc. Neoplasm-specific polypeptides and their uses
PT1735348E (pt) 2004-03-19 2012-07-24 Imclone Llc Anticorpo anti-receptor do factor de crescimento humano
WO2005100998A2 (en) * 2004-04-16 2005-10-27 Europroteome Ag Membrane markers for use in cancer diagnosis and therapy
WO2006002378A2 (en) 2004-06-23 2006-01-05 Avalon Pharmaceuticals Determining cancer-linked genes and therapeutic targets using molecular cytogenetic methods
CA2594482C (en) 2005-01-19 2013-10-01 Zeria Pharmaceutical Co., Ltd. Antitumor agent
RU2438705C2 (ru) 2005-01-21 2012-01-10 Дженентек, Инк. Введение фиксированных доз her-антител
JP5006802B2 (ja) 2005-02-18 2012-08-22 チルドレンズ メディカル センター コーポレイション 上皮由来の癌診断および予後診断のためのバイオマーカーとしてのＣｙｒ６１
WO2006099126A2 (en) 2005-03-11 2006-09-21 Ciphergen Biosystems, Inc. Biomarkers for ovarian cancer and endometrial cancer: hepcidin
JP2006316040A (ja) 2005-05-13 2006-11-24 Genentech Inc Ｈｅｒｃｅｐｔｉｎ（登録商標）補助療法
US8014957B2 (en) 2005-12-15 2011-09-06 Fred Hutchinson Cancer Research Center Genes associated with progression and response in chronic myeloid leukemia and uses thereof
CA2635616A1 (en) * 2006-01-05 2007-07-19 Carlo M. Croce Microrna expression abnormalities in pancreatic endocrine and acinar tumors
WO2007095186A2 (en) 2006-02-14 2007-08-23 Dana-Farber Cancer Institute, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of cancer
WO2008073162A2 (en) 2006-08-17 2008-06-19 Cell Signaling Technology, Inc. Lysine acetylation sites
US20080107668A1 (en) 2006-08-30 2008-05-08 Immunotope, Inc. Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
US7615349B2 (en) 2006-09-07 2009-11-10 H. Lee Moffitt Cancer Center And Research Institute, Inc. Melanoma gene signature
WO2008059252A2 (en) 2006-11-15 2008-05-22 Oxford Biomedica (Uk) Limited Methods and composition fro t cell receptors which recognize 5t4 antigen
EP3106874B1 (en) 2007-10-25 2020-04-01 Toray Industries, Inc. Method for detection of cancer
JP5663834B2 (ja) 2008-03-14 2015-02-04 東ソー株式会社 遺伝子組換え抗体の製造方法
AU2009225877B2 (en) 2008-03-18 2014-11-20 Genentech, Inc. Combinations of an anti-HER2 antibody-drug conjugate and chemotherapeutic agents, and methods of use
CA2732980C (en) 2008-08-05 2017-08-15 Toray Industries, Inc. Caprin-1 as a target for diagnosing cancer
PL2322221T3 (pl) 2008-08-05 2015-01-30 Toray Industries Kompozycja farmaceutyczna do leczenia i zapobiegania raka
BR122020027042B1 (pt) 2008-08-05 2022-11-08 Toray Industries, Inc Uso de um agente indutor de imunidade, uso de um polipeptídeo e uso de um vetor recombinante
MX2012001741A (es) 2009-08-19 2012-03-21 Merck Patent Gmbh Anticuerpos para la deteccion de complejos de integrina en material incrustado en parafina fijado con formalina (ffpe).
CA2773240C (en) 2009-09-22 2015-11-10 Volker Sandig Process for producing molecules containing specialized glycan structures
ES2691738T3 (es) 2010-02-04 2018-11-28 Toray Industries, Inc. Agente farmacéutico para el tratamiento y/o la prevención de cáncer
MX340016B (es) 2010-02-04 2016-06-22 Toray Industries Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
DK2532680T3 (da) 2010-02-04 2015-07-20 Toray Industries Medicinsk sammensætning til behandling og/eller forebyggelse af cancer
CN102822335B (zh) 2010-02-04 2015-09-30 东丽株式会社 癌的治疗和/或预防用药物组合物
EP2532365B1 (en) 2010-02-04 2016-05-04 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of cancer
PT2532366T (pt) 2010-02-04 2016-12-20 Toray Industries Composição farmacêutica para o tratamento e/ou prevenção de cancro
WO2012005550A2 (ko) 2010-07-08 2012-01-12 강원대학교산학협력단 담낭암 치료용 약제학적 조성물 및 이를 이용한 담낭암의 성장, 전이 억제 및 치료 방법
CN103261224B (zh) 2010-07-26 2015-10-07 瑟维尔实验室 用于肝癌治疗的方法和组合物
CN103764825B (zh) * 2011-08-04 2015-09-02 东丽株式会社 癌的治疗和/或预防用药物组合物
PL2740794T3 (pl) 2011-08-04 2018-09-28 Toray Industries, Inc. Kompozycja farmaceutyczna do leczenia i/lub profilaktyki nowotworów
HUE033628T2 (en) 2011-08-04 2017-12-28 Toray Industries Method for detecting pancreatic cancer
US9273128B2 (en) 2011-08-04 2016-03-01 Toray Industries, Inc Pharmaceutical composition for treatment and/or prophylaxis of cancer
CN103717238B (zh) 2011-08-04 2016-10-12 东丽株式会社 胰癌的治疗和/或预防用药物组合物
US9180188B2 (en) * 2011-08-04 2015-11-10 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prophylaxis of cancer
CA2844038C (en) * 2011-08-04 2019-05-07 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prophylaxis of cancer
MX363136B (es) * 2012-02-21 2019-03-12 Toray Industries Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
ES2643241T3 (es) * 2012-02-21 2017-11-21 Toray Industries, Inc. Composición medicinal para tratar y/o prevenir el cáncer
ES2739380T3 (es) * 2012-02-21 2020-01-30 Toray Industries Composición farmacéutica para el tratamiento del cáncer
DK2818482T3 (da) * 2012-02-21 2019-07-15 Toray Industries Farmaceutisk sammensætning til behandling af cancer
RU2640245C2 (ru) 2012-03-30 2017-12-27 Торэй Индастриз, Инк. Фармацевтическая композиция для лечения и/или предотвращения рака печени
JP6107655B2 (ja) 2012-03-30 2017-04-05 東レ株式会社 胆嚢癌の治療及び／又は予防用医薬組成物
CA2918989C (en) 2013-08-09 2021-11-02 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of cancer

Also Published As

Publication number Publication date
CA2844033A1 (en) 2013-02-07
AU2012290948B2 (en) 2017-05-25
BR112014002616B1 (pt) 2022-01-18
RU2624040C2 (ru) 2017-06-30
CN103718045A (zh) 2014-04-09
CA2844033C (en) 2021-07-27
AU2012290948A1 (en) 2014-03-20
KR101984554B1 (ko) 2019-05-31
PT2741085T (pt) 2017-06-30
MX349907B (es) 2017-08-18
EP2741085A4 (en) 2015-03-04
ES2629061T3 (es) 2017-08-07
KR20140048318A (ko) 2014-04-23
WO2013018885A1 (ja) 2013-02-07
PL2741085T3 (pl) 2017-09-29
US9796775B2 (en) 2017-10-24
JPWO2013018885A1 (ja) 2015-03-05
EP2741085B1 (en) 2017-04-05
RU2014108048A (ru) 2015-09-10
BR112014002616A2 (pt) 2019-03-19
CN103718045B (zh) 2016-08-17
DK2741085T3 (en) 2017-06-19
JP6094220B2 (ja) 2017-03-15
US20140179558A1 (en) 2014-06-26
EP2741085A1 (en) 2014-06-11
HUE033628T2 (en) 2017-12-28

Similar Documents

Publication Publication Date Title
MX349907B (es) Metodo para detectar cancer pancreatico.
MX358772B (es) Metodo para detectar cancer.
CY1123708T1 (el) Αντισωματα που συνδεονται προς τον ανθρωπινο προσδετη 1 (pd-l1) προγραμματισμενου θανατου
MX357292B (es) Método para detectar cáncer.
CL2012003375A1 (es) Anticuerpo monoclonal que se une a enzima ariloxialcanoato dioxigenasa (aad-12); linea celular de hibridomas que produce dicho anticuerpo; metodos para detectar la presencia de la enzima aad-12; metodo para la deteccion cuantitativa de una enzima aad-12.
CY1121291T1 (el) Ανοσοδοκιμασιες ενισχυσης σηματος
NZ593514A (en) p-mTOR and p-AKT as Ratio Based Biomarkers for the Prognosis and/or Diagnosis of Cancer
BR112016004437A2 (pt) métodos de imunoteste e de seleção de linhagem de células, anticorpos e kit
MX368394B (es) Receptor alfa de folato como marcador de diagnostico y pronostico para canceres que expresan receptor alfa de folato.
CL2012000914A1 (es) Anticuerpos monoclonales que se unen especificamente a la region c-terminal de progastrina. uso para la preparacion de un medicamento util en el tratamiento de cancer colorectal.
BRPI0906903B8 (pt) anticorpo monoclonal e método de detecção da expressão de cd70
IN2014MN00873A (es)
MX2015012823A (es) Ensayo de combinacion de antigeno-anticuerpo del virus de la hepatitis c (vhc) y metodos y composiciones para usarlo.
MX374652B (es) Ensayos para detectar la presencia o la cantidad de un anticuerpo antifármaco.
EA201370063A1 (ru) Фосфолипидом рака
BR112016007037A2 (pt) método para detectar câncer pancreático, anticorpo monoclonal e kit
BR112018007842A2 (pt) imunoensaio para a detecção de cininogênio clivado de alto peso molecular, método, anticorpo isolado, kit para detectar um cininogênio de alto peso molecular clivado (hmwk)
RU2015104737A (ru) Способ обнаружения мультиспецифического связывающего агента
WO2012125805A3 (en) Protein biomarkers for the diagnosis of prostate cancer
WO2012155134A3 (en) Assay reagents for a neurogranin diagnostic kit
MX2013004230A (es) Uso de compuestos mejoradores de señal en deteccion de electroquimioluminiscencia.
EP2386633A4 (en) NEW TUMORANT EEF2
GB201119585D0 (en) Assay
EA201500377A1 (ru) Способ обнаружения анализируемого вещества и определение его концентрации с использованием намагничиваемых гранул
WO2011137389A3 (en) Compositions and methods for reliably detecting and/or measuring the amount of a modified target protein in a sample

Legal Events

Date Code Title Description
FG Grant or registration